HEALTHCARE TODAY
  • IN THE SPOTLIGHT
  • DIGITAL HEALTH
  • PRODUCTS & SUPPLEMENTS
  • HEALTH A - Z
  • PARENTING
  • MEN'S HEALTH
  • WOMEN
  • AGEING
  • NUTRITION
  • FITNESS
  • COMPLIMENTARY MEDICINE
  • ABOUT US
  • IN THE SPOTLIGHT
  • DIGITAL HEALTH
  • PRODUCTS & SUPPLEMENTS
  • HEALTH A - Z
  • PARENTING
  • MEN'S HEALTH
  • WOMEN
  • AGEING
  • NUTRITION
  • FITNESS
  • COMPLIMENTARY MEDICINE
  • ABOUT US
Search

TECENTRIQ, A PD-L1 INHIBITOR FOR ADVANCED LUNG CANCER PATIENTS

 
SEP 30, 2018 10 PM
Picture
(Left to right: Family Medicine Specialist Dr Raja Ahmad Shaharul, Roche (Malaysia) general manager Lance Duan, Head of Lung and Thoracic Oncology Centre Professor Dr. Rolf Stahel and Dato’ Dr Mohamed Ibrahim launching Tecentriq.
FAST FACTS

Lung cancer is the leading cause of death. 
Worldwide (2012)
  • 1.8 million were diagnosed
  • 1.6 million succumbed to the disease
Malaysia
  • Lung cancer is the second most common cause of death with 4,088 deaths per year.
  • Non-small cell lung cancer (NSCLC) accounts for 85 per cent of all lung cancer cases.
  • Common symptoms of lung cancer include persistent coughing, shortness of breath, chest pains, fatigue, loss of appetite and weight loss.
Roche (Malaysia) Sdn Bhd recently launched Tecentriq (atezolizumab), a programmed death-ligand 1 (PD-L1) inhibitor approved in Malaysia for the treatment of patients with non-small cell lung cancer (NSCLC). 

An approved cancer immunotherapy designed to target the PD-L1 protein, Tecentriq is formulated to work with the body’s immune system to attack cancer cells.

In a healthy immune system, the molecule PD-L1, which is found on T-cells, works as a ‘stop switch’ that prevents them from attacking normal cells. Some cancer cells that contain a large amount of PD-L1 can avoid being detected and destroyed by the T-cells. Tecentriq functions to block the activity of PD-L1, thereby stimulating the immune response against cancer cells .     

Late diagnosis
“One of the main challenges in the treatment of lung cancer is late diagnosis, as patients may not have much symptoms until the cancer has advanced," said Medical Director Dato’ Dr Mohamed Ibrahim bin Dato’ A. Wahid.

"In Malaysia, 75-88 per cent of cases are diagnosed in Stages III, during which treatment is largely to control the tumour or for palliation. The emergence of immunotherapy presents a viable treatment due to its low side effects and high tolerability profiles. It is recommended for patients with advanced disease or whose platinum-based chemotherapy or targeted therapy is not working." 
Picture

IN THE SPOTLIGHT

HEALTH A - Z

MEN'S HEALTH

AGEING

NUTRITION

ABOUT US

PRODUCTS & SUPPLEMENTS

PARENTING

WOMEN

FITNESS

​COMPLIMENTARY MEDICINE

BM
​Copyright@ 2018 Healthcare Today. All rights reserved. The material in this site is intended to be of general information use and is not intended to constitute medical
advice, probable diagnosis or recommended treatments.                                                              
  • IN THE SPOTLIGHT
  • DIGITAL HEALTH
  • PRODUCTS & SUPPLEMENTS
  • HEALTH A - Z
  • PARENTING
  • MEN'S HEALTH
  • WOMEN
  • AGEING
  • NUTRITION
  • FITNESS
  • COMPLIMENTARY MEDICINE
  • ABOUT US